5451-40-1 | 2,6-Dichloropurine

Packsize	Purity	Availability	Price	Discounted Price
1g	97%	in stock	$8.00	$5.00
5g	98%	in stock	$10.00	$7.00
10g	98%	in stock	$15.00	$11.00
25g	95%	in stock	$30.00	$21.00
50g	95%	in stock	$59.00	$41.00
100g	98%	in stock	$97.00	$68.00
500g	98%	in stock	$478.00	$335.00

Description

• Catalog Number: AB43703
• Chemical Name: 2,6-Dichloropurine
• CAS Number: 5451-40-1
• Molecular Formula: C5H2Cl2N4
• Molecular Weight: 189.0022
• MDL Number: MFCD09749894
• SMILES: Clc1nc(Cl)c2c(n1)nc[nH]2
• NSC Number: 18395

Computed Properties

• Complexity: 155
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 11
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• XLogP3: 1.7

Literature

• Two tautomeric polymorphs of 2,6-dichloropurine.

  Acta crystallographica. Section C, Crystal structure communications 20111201

• Direct C-H arylation of purine on solid phase and its use for chemical libraries synthesis.

  ACS combinatorial science 20110912

• Solid-phase synthesis of highly diverse purine-hydroxyquinolinone bisheterocycles.

  Journal of combinatorial chemistry 20101108

• A class of novel conjugates of substituted purine and Gly-AA-OBzl: synthesis and evaluation of orally analgesic activity.

  Bioorganic & medicinal chemistry letters 20101015

• Inhibition of human immunodeficiency virus type-1 by cdk inhibitors.

  AIDS research and therapy 20100101

• UVC induced oxidation of chloropurines: excited singlet and triplet pathways for the photoreaction.

  Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 20080901

• Two specific drugs, BMS-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways.

  AIDS research and therapy 20080101

• New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile.

  Purinergic signalling 20070901

• Structure and synthesis of 6-(substituted-imidazol-1-yl)purines: versatile substrates for regiospecific alkylation and glycosylation at N9.

  The Journal of organic chemistry 20060526

• Synthesis and Ca2+-mobilizing activity of purine-modified mimics of adenophostin A: a model for the adenophostin-Ins(1,4,5)P3 receptor interaction.

  Journal of medicinal chemistry 20031106

• An efficient synthesis of 2-substituted 6-methylpurine bases and nucleosides by Fe- or Pd-catalyzed cross-coupling reactions of 2,6-dichloropurines.

  The Journal of organic chemistry 20030711

• Purine and deazapurine nucleosides: synthetic approaches, molecular modelling and biological activity.

  Farmaco (Societa chimica italiana : 1989) 20030301

• Nucleic acid related compounds. 118. Nonaqueous diazotization of aminopurine derivatives. Convenient access to 6-halo- and 2,6-dihalopurine nucleosides and 2'-deoxynucleosides with acyl or silyl halides.

  The Journal of organic chemistry 20030124

• Catalysis of nucleophilic aromatic substitutions in the 2,6,8-trisubstituted purines and application in the synthesis of combinatorial libraries.

  Molecular diversity 20030101

• Nucleic acid related compounds. 116. Nonaqueous diazotization of aminopurine nucleosides. Mechanistic considerations and efficient procedures with tert-butyl nitrite or sodium nitrite.

  The Journal of organic chemistry 20020920

• Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1.

  Bioorganic & medicinal chemistry 20020901

• 5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors.

  Journal of medicinal chemistry 20010830

• Synthesis and biological activity of 4'-C-hydroxymethyl-2'-fluoro-D-arabinofuranosylpurine nucleosides.

  Nucleosides, nucleotides & nucleic acids 20010101

• Coupling of 2,6-disubstituted purines to ribose-modified sugars.

  Nucleosides, nucleotides & nucleic acids 20010101

• Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.

  Antimicrobial agents and chemotherapy 20000801

• A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

  Antimicrobial agents and chemotherapy 19990801

• Structure-activity relationships for the binding of ligands to xanthine or guanine phosphoribosyl-transferase from Toxoplasma gondii.

  Biochemical pharmacology 19951109